SCHEMBL5258486

SCHEMBL5258486

Cc1cc(C)nc(Nc2ccc(-c3nc4ccccc4s3)cc2C)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MAPT P10636 8/20 0.56
AURKA O14965 1/20 0.56
EGFR P00533 1/20 0.56
KDR P35968 1/20 0.56
TEK Q02763 1/20 0.56
AURKB Q96GD4 1/20 0.56
APP P05067 5/20 0.55
TP53 P04637 2/20 0.54
LMNA P02545 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
RXFP1 Q9HBX9 1/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
GLA P06280 2/20 0.49
GAA P10253 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260053 0.90 TP53 (0.63) SMN1; SMN2NPC1RAB9AMAPTAPP
SCHEMBL5260609 0.85 RAB9A (0.55) SMN1; SMN2NPC1RAB9AMAPTAURKA
SCHEMBL5263632 0.83 APP (0.63) SMN1; SMN2NPC1RAB9AMAPTAURKA
SCHEMBL5259397 0.81 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9AMAPTAURKA
SCHEMBL14156493 0.78 MAPT (0.65) SMN1; SMN2NPC1RAB9AMAPTAPP
SCHEMBL29935542 0.75 KDM4E (0.64) SMN1; SMN2NPC1RAB9AMAPTAPP
SCHEMBL29406270 0.74 APP (0.69) SMN1; SMN2NPC1RAB9AMAPTAPP
SCHEMBL8373442 0.74 MAPT (0.68) SMN1; SMN2NPC1RAB9AMAPTAPP
SCHEMBL30466256 0.74 MAPT (0.68) SMN1; SMN2NPC1RAB9AMAPTAPP
SCHEMBL6336000 0.74 TP53 (0.55) SMN1; SMN2NPC1RAB9AMAPTAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 SMN1; SMN2 1665/4885NPC1 4075/4885RAB9A 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.